Description: Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Home Page: www.sparc.life
17/B, Mahal Industrial Estate
Mumbai,
400093
India
Phone:
91 22 6645 5645
Officers
| Name | Title |
|---|---|
| Mr. Anilkumar Raghavan | Chief Executive Officer |
| Mr. Anup Rathi | Chief Financial Officer |
| Dr. Nitin Dharmadhikari | Chief Operating Officer |
| Mr. Jaydeep Issrani | Senior General Manager of Business Development, Corporate Communication & Investor Relations |
| Ms. Kajal K. Damania | Company Secretary & Compliance Officer |
| Ms. Shanta Gupta | Chief Human Resource Officer |
| Mr. Siu-Long Yao | Head Clinical Development |
| Dr. Nitin K. Damle Ph.D. | Chief Innovation Officer |
| Dr. Yashoraj Zala | Head of Drug Delivery Systems |
| Dr. Vikram K. Ramanathan | Head of Preclinical Development |
Exchange: NSE
Country: IN : India
Currency: Indian Rupee (INR)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 55.9418 |
| Price-to-Sales TTM: | 117.0725 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 409 |